LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 1 | H09 | 72 | hr | 1401 | 1542 | 4223 | 0.3651 | 0.0498 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 2 | H09 | 72 | hr | 1401 | 1386 | 4223 | 0.3282 | -0.0055 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 3 | H09 | 72 | hr | 1401 | 1567 | 4223 | 0.3711 | 0.0586 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 1 | G09 | 72 | hr | 1401 | 1378 | 4223 | 0.3263 | -0.0083 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 2 | G09 | 72 | hr | 1401 | 1121 | 4223 | 0.2655 | -0.0994 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 3 | G09 | 72 | hr | 1401 | 1341 | 4223 | 0.3175 | -0.0215 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 1 | F03 | 72 | hr | 1401 | 1335 | 4223 | 0.3161 | -0.0236 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 2 | F03 | 72 | hr | 1401 | 1250 | 4223 | 0.2960 | -0.0537 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 3 | F03 | 72 | hr | 1401 | 1108 | 4223 | 0.2624 | -0.1040 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 1 | G03 | 72 | hr | 1401 | 896 | 4223 | 0.2122 | -0.1792 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 2 | G03 | 72 | hr | 1401 | 946 | 4223 | 0.2240 | -0.1614 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 3 | G03 | 72 | hr | 1401 | 962 | 4223 | 0.2278 | -0.1558 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 1 | P15 | 72 | hr | 1401 | 3879 | 4223 | 0.9185 | 0.8781 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 2 | P15 | 72 | hr | 1401 | 4008 | 4223 | 0.9491 | 0.9238 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 3 | P15 | 72 | hr | 1401 | 4012 | 4223 | 0.9500 | 0.9252 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 1 | A09 | 72 | hr | 1401 | 2239 | 4223 | 0.5302 | 0.2968 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 2 | A09 | 72 | hr | 1401 | 2012 | 4223 | 0.4764 | 0.2164 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 3 | A09 | 72 | hr | 1401 | 2173 | 4223 | 0.5146 | 0.2734 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 1 | I09 | 72 | hr | 1401 | 4870 | 4223 | 1.1532 | 1.2293 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 2 | I09 | 72 | hr | 1401 | 3737 | 4223 | 0.8849 | 0.8277 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 3 | I09 | 72 | hr | 1401 | 4177 | 4223 | 0.9891 | 0.9837 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1401 | 2926 | 4223 | 0.6929 | 0.5403 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1401 | 3453 | 4223 | 0.8177 | 0.7271 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1401 | 3781 | 4223 | 0.8953 | 0.8433 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 1 | P09 | 72 | hr | 1401 | 3373 | 4223 | 0.7987 | 0.6987 |